WO2024089638 - NUCLEIC ACID BASED VACCINE
National phase entry:
Publication Number
WO/2024/089638
Publication Date
02.05.2024
International Application No.
PCT/IB2023/060807
International Filing Date
26.10.2023
Title **
[English]
NUCLEIC ACID BASED VACCINE
[French]
VACCIN À BASE D'ACIDE NUCLÉIQUE
Applicants **
GLAXOSMITHKLINE BIOLOGICALS SA
Inventors
PETSCH, Benjamin
VAHRENHORST, Dominik
CHAVES MORENO, Diego
GERGEN, Janina
DEVANT, Jessica Michelle
KOVACIKOVA, Kristina
GROBE, Hans Wolfgang
Priority Data
2216023.8
28.10.2022
GB
2300950.9
23.01.2023
GB
2308048.4
30.05.2023
GB
2311985.2
04.08.2023
GB
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 7632 | |
| EPO | Filing, Examination, Granting | 29239 | |
| Japan | Filing, Examination, Granting | 2587 | |
| South Korea | Filing, Examination, Granting | 3049 | |
| USA | Filing, Examination, Granting | 10140 |
Total:
52,647
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present invention is directed to nucleic acids suitable for use in treatment or prophylaxis of an infection with a coronavirus, such as a Coronavirus SARS-CoV-2 variant, or a disorder related to such an infection, such as COVID-19. The present invention is also directed to compositions, and vaccines. The compositions and vaccines comprise at least one of said nucleic acid sequences, and nucleic acid sequences in association with a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acids, the composition, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, such as a Coronavirus infection from a SARS-CoV-2 variant.[French]
La présente invention concerne des acides nucléiques appropriés pour une utilisation dans le traitement ou la prophylaxie d'une infection par un coronavirus, tel qu'un variant du coronavirus SARS-CoV-2 ou un trouble associé à une telle infection, telle que la COVID-19. La présente invention concerne également des compositions et des vaccins. Les compositions et les vaccins comprennent au moins l'une desdites séquences d'acide nucléique et des séquences d'acide nucléique en association avec une nanoparticule lipidique (LNP). L'invention concerne également des première et seconde utilisations médicales des acides nucléiques, de la composition, du vaccin et du kit, ainsi que des méthodes de traitement ou de prévention d'une infection à coronavirus, telle qu'une infection à coronavirus à partir d'un variant du SARS-CoV-2.